CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later
| Autor: | Sancy A. Leachman, Tammy K. Stump, Marjan Champine, Wendy Kohlmann, Lisa G. Aspinwall, Danielle M. Drummond, Tracy Petrie, B. Liley, Pamela B. Cassidy, Jennifer M. Taber |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Heterozygote Adolescent Sun protection Genetic counseling Sunburn CDKN2A-p16+ Genetic Counseling Article 03 medical and health sciences Young Adult 0302 clinical medicine CDKN2A Internal medicine Medicine Humans 030212 general & internal medicine Genetic Testing Prospective Studies Family history Ultraviolet radiation familial melanoma Genetics (clinical) Cyclin-Dependent Kinase Inhibitor p16 CDKN2A/p16 Aged Melanins sun protection sunburns business.industry Control group design Middle Aged Radiation Exposure 3. Good health Pedigree genetic counseling and testing 030220 oncology & carcinogenesis Case-Control Studies Mutation Sunlight Female Sun exposure business |
| Zdroj: | Genetics in medicine : official journal of the American College of Medical Genetics |
| ISSN: | 1530-0366 1098-3600 |
| Popis: | This study investigated whether genetic counseling and test reporting for the highly penetrant CDKN2A melanoma predisposition gene promoted decreases in sun exposure. A prospective, nonequivalent control group design compared unaffected participants (N = 128, Mage = 35.24, 52% men) from (1) families known to carry a CDKN2A pathogenic variant, who received counseling about management recommendations and a positive or negative genetic test result and (2) no-test control families known not to carry a CDKN2A pathogenic variant, who received equivalent counseling based on their comparable family history. Changes in daily ultraviolet radiation (UVR) exposure (J/m2), skin pigmentation (melanin index), and sunburns between baseline and one year following counseling were compared among carriers (n = 32), noncarriers (n = 46), and no-test control participants (n = 50). Both carriers and no-test control participants exhibited a decrease one year later in daily UVR dose (B = −0.52, −0.33, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink